In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Koen van Besien argues that there is no value to the use of brentuximab vedotin as consolidation therapy following auto-SCT in Hodgkin Lymphoma.
A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP
© 2015 Imedex, LLC.